Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.34 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12219647 | 0.94 | KMT2A (0.50) | KMT2AMEN1DNM1LMNAALDH1A1 | |
| SCHEMBL17663571 | 0.91 | KMT2A (0.54) | KMT2AMEN1DNM1MCL1LMNA | |
| SCHEMBL9921469 | 0.88 | CASP2 (0.46) | KMT2ADNM1LMNAALDH1A1KDM4E | |
| SCHEMBL16316310 | 0.84 | KMT2A (0.61) | KMT2AMEN1DNM1LMNAALDH1A1 | |
| SCHEMBL13033284 | 0.84 | CASP2 (0.48) | KMT2ADNM1ALDH1A1HPGD | |
| SCHEMBL9921462 | 0.84 | PAOX (0.46) | KMT2AMEN1LMNAALDH1A1SLC22A2 | |
| SCHEMBL19057368 | 0.82 | KMT2A (0.58) | KMT2AMEN1DNM1LMNAALDH1A1 | |
| SCHEMBL16357815 | 0.81 | MEN1 (0.44) | KMT2AMEN1DNM1LMNAALDH1A1 | |
| SCHEMBL10964537 | 0.79 | KMT2A (0.56) | KMT2AMEN1DNM1LMNAALDH1A1 | |
| SCHEMBL21950089 | 0.79 | KMT2A (0.40) | KMT2AMEN1DNM1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921111-B2 | Polymer based polynucleotide transfection agents | INTEZYNE TECHNOLOGIES (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140302607-A1 | POLYMER BASED POLYNUCLEOTIDE TRANSFECTION AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20120237565-A1 | PEGYLATED POLYPLEXES CONTAINING TWO OR MORE DIFFERENT POLYMERS FOR POLYNUCLEOTIDE DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120148631-A1 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011130577-A1 | CONTROLLED POLYPLEX ASSEMBLY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20110256227-A1 | CONTROLLED POLYPLEX ASSEMBLY | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110256227-A1 | CONTROLLED POLYPLEX ASSEMBLY | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110229528-A1 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011113065-A2 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148631-A1 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | PARN, PUF60, PARG | KMT2A 3658/4885MEN1 3205/4885DNM1 295/4885 |
| US-20120237565-A1 | PEGYLATED POLYPLEXES CONTAINING TWO OR MORE DIFFERENT POLYMERS FOR POLYNUCLEOTIDE DELIVERY | PARN, PARG, PUF60 | KMT2A 3531/4885MEN1 2969/4885DNM1 430/4885 |
| US-20110229528-A1 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | PARN, PUF60, PARG | KMT2A 3658/4885MEN1 3205/4885DNM1 295/4885 |
| US-20110256227-A1 | CONTROLLED POLYPLEX ASSEMBLY | PARG, PARN, PUF60 | KMT2A 2343/4885MEN1 1587/4885DNM1 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.